https://doi.org/10.4081/vl.2026.14670
A case series study - treatment of chronic wounds with Erbium:YAG laser
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 March 2026
The objective of this case series was to evaluate the effectiveness and safety of Erbium:YAG (Er:YAG) laser therapy, using both ablative and RecoSMA stimulation modes, in treating Chronic Lower Extremity Wounds (CLEWs).
This prospective single-center case series included 24 patients (20 completed the study) with chronic wounds of venous, arterial, or mixed etiology. Patients with arterial or mixed CLEWs received an alginate wound dressing containing antimicrobial silver. Those with venous ulcers additionally received compression therapy using the UNNA BOOT. All patients underwent weekly sessions combining ablative Er:YAG debridement and RecoSMA stimulation. Outcomes included time to complete epithelialization, reduction in wound area, and adverse events. Wound area was measured using digital planimetry with standardized photographic documentation.
Twelve patients achieved complete wound epithelialization (mean healing time: 4.5 weeks, Standard Deviation, SD, 3.8), two had partial improvement, and six showed no significant change. No adverse events were reported. Statistical analysis showed no significant correlation between healing outcomes and common risk factors such as age, diabetes, obesity, or stasis dermatitis.
Combined Er:YAG laser debridement and biostimulation with RecoSMA is a safe and promising adjunct therapy for CLEWs, promoting healing without the need for anesthesia. Further randomized controlled trials are warranted to validate long-term efficacy.
Downloads
1. Schneider C, Stratman S, Kirsner RS. Lower extremity ulcers. Med Clin North Am 2021;105:663-79. DOI: https://doi.org/10.1016/j.mcna.2021.04.006
2. Alcolea JM, Hernández E, Martínez-Carpio PA, et al. Treatment of chronic lower extremity ulcers with a new ER:YAG laser technology. Laser Ther 2017;26:211-22. DOI: https://doi.org/10.5978/islsm.17-OR-17
3. Chilgar RM, Andurkar SP. Spatially modulated erbium YAG laser as a treatment for diabetic ulcer. J Wound Care 2023;32:S21-9. DOI: https://doi.org/10.12968/jowc.2023.32.Sup10a.S21
4. Zaitsev AE, Asanov ON. Erbium:Yttrium Aluminium Garnet (Er:YAG) laser therapy versus sharp debridement in the management of chronic ulcers of the lower extremity: a randomised control trial. Int Wound J 2025;22:e70688. DOI: https://doi.org/10.1111/iwj.70688
5. Caliskan E, Botsali A. Combination of full-field and fractional Erbium:YAG laser for nonhealing wounds. Dermatol Surg 2022;48:114-9. DOI: https://doi.org/10.1097/DSS.0000000000003292
6. Qiu Y, Osadnik CR, Team V, Weller CD. Effects of physical activity as an adjunct treatment on healing outcomes and recurrence of venous leg ulcers: a scoping review. Wound Repair Regen 2022;30:172-85. DOI: https://doi.org/10.1111/wrr.12995
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
